All Relations between Depression and serotonin

Publication Sentence Publish Date Extraction Date Species
Lukas Pezawas, Andreas Meyer-Lindenberg, Emily M Drabant, Beth A Verchinski, Karen E Munoz, Bhaskar S Kolachana, Michael F Egan, Venkata S Mattay, Ahmad R Hariri, Daniel R Weinberge. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nature neuroscience. vol 8. issue 6. 2005-08-02. PMID:15880108. carriers of the short allele of a functional 5' promoter polymorphism of the serotonin transporter gene have increased anxiety-related temperamental traits, increased amygdala reactivity and elevated risk of depression. 2005-08-02 2023-08-12 human
Jonathan P Roiser, Andrew McLean, Alan D Ogilvie, Andrew D Blackwell, Diane J Bamber, Ian Goodyer, Peter B Jones, Barbara J Sahakia. The subjective and cognitive effects of acute phenylalanine and tyrosine depletion in patients recovered from depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 4. 2005-07-28. PMID:15688090. it is hypothesized that tests involving reward/punishment processing are preferentially affected by da depletion, and that a more complete account of depression is likely to result from considering the roles played by serotonin, noradrenaline, and da in mediating the various cognitive and clinical symptoms, including anhedonia. 2005-07-28 2023-08-12 human
Rebecca Segrave, Pradeep J Natha. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Human psychopharmacology. vol 20. issue 3. 2005-07-27. PMID:15648095. pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. 2005-07-27 2023-08-12 Not clear
Holger Rosenbrock, Anita Bloching, Carmen Weiss, Franco Borsin. Partial serotonergic denervation decreases progenitor cell proliferation in the adult rat hippocampus, but has no effect on rat behavior in the forced swimming test. Pharmacology, biochemistry, and behavior. vol 80. issue 4. 2005-07-27. PMID:15820524. it has been hypothesized that impaired serotonin (5-ht) neurotransmission contributes to the pathophysiology of depression. 2005-07-27 2023-08-12 rat
Holger Rosenbrock, Anita Bloching, Carmen Weiss, Franco Borsin. Partial serotonergic denervation decreases progenitor cell proliferation in the adult rat hippocampus, but has no effect on rat behavior in the forced swimming test. Pharmacology, biochemistry, and behavior. vol 80. issue 4. 2005-07-27. PMID:15820524. these findings indicate a regulative role of 5-ht for hippocampal progenitor cell proliferation and neurogenesis, but its relation to animal models of depression remains to be elucidated. 2005-07-27 2023-08-12 rat
D A F Robertson, J E Beattie, I C Reid, D J K Balfou. Regulation of corticosteroid receptors in the rat brain: the role of serotonin and stress. The European journal of neuroscience. vol 21. issue 6. 2005-07-26. PMID:15845079. it has been suggested that physiological resistance to repeated stress is associated with increased 5-hydroxytryptamine (5-ht) release in the dorsal hippocampus and that dysregulation of this neuroadaptation may be implicated in the psychopathology of depression. 2005-07-26 2023-08-12 rat
F Jenck, M Bös, J Wichmann, H Stadler, J R Martin, J L Morea. The role of 5-HT2C receptors in affective disorders. Expert opinion on investigational drugs. vol 7. issue 10. 2005-07-26. PMID:15991903. 5-ht(2c) receptors are predominantly localised in the brain and their dysregulation may contribute to particular symptoms of anxiety and depression. 2005-07-26 2023-08-12 human
D T Won. Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Expert opinion on investigational drugs. vol 7. issue 10. 2005-07-26. PMID:15991911. duloxetine offers an opportunity to utilise combined central 5-ht and ne neuronal pathways to improve the treatment of patients with major depression. 2005-07-26 2023-08-12 mouse
J Fennell, M Hussai. Serotonin syndrome:case report and current concepts. Irish medical journal. vol 98. issue 5. 2005-07-26. PMID:16010782. selective serotonin reuptake inhibitors (ssri's) are increasingly being used as the first line therapeutic agent for the depression. 2005-07-26 2023-08-12 Not clear
M-P Pancrazi, P Metai. [Treatment of the psychological and behavioural disorders of Alzheimer's disease]. Presse medicale (Paris, France : 1983). vol 34. issue 9. 2005-07-20. PMID:15988346. some selective serotonin reuptake inhibitors agents may be useful not only in depression but also anxiety, emotional disturbances, irritability and compulsiveness. 2005-07-20 2023-08-12 Not clear
Michael E Thase, Pierre V Tran, Curtis Wiltse, Beth A Pangallo, Craig Mallinckrodt, Michael J Detk. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. Journal of clinical psychopharmacology. vol 25. issue 2. 2005-07-15. PMID:15738744. this analysis assessed the effects of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, on indices of cardiovascular safety, including heart rate, blood pressure (bp), and electrocardiograms (ecgs), in a large group of clinical trial patients with depression. 2005-07-15 2023-08-12 Not clear
Patrick Osei-Owusu, Amy James, James Crane, Karie E Scrogi. 5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome. The Journal of pharmacology and experimental therapeutics. vol 313. issue 3. 2005-07-14. PMID:15743927. neuroendocrine responses to administration of serotonin releasing agents or 5-hydroxytryptamine (5-ht) 1a receptor agonists have been used as an index of serotonin receptor function in patients with depression and other mood disorders. 2005-07-14 2023-08-12 rat
Paul Willner, Anthony S Hale, Spilios Argyropoulo. Dopaminergic mechanism of antidepressant action in depressed patients. Journal of affective disorders. vol 86. issue 1. 2005-07-12. PMID:15820269. the participants were patients diagnosed with major depressive disorder (n = 8) who had been treated successfully (hamilton depression scale < 10) with selective serotonin uptake inhibitors (fluoxetine, citalopram or paroxetine); and age-matched, non-depressed, untreated volunteers (n = 10). 2005-07-12 2023-08-12 human
C Mizrahi, A Stojanovic, M Urbina, I Carreira, L Lim. Differential cAMP levels and serotonin effects in blood peripheral mononuclear cells and lymphocytes from major depression patients. International immunopharmacology. vol 4. issue 8. 2005-07-11. PMID:15270025. differential camp levels and serotonin effects in blood peripheral mononuclear cells and lymphocytes from major depression patients. 2005-07-11 2023-08-12 human
C Mizrahi, A Stojanovic, M Urbina, I Carreira, L Lim. Differential cAMP levels and serotonin effects in blood peripheral mononuclear cells and lymphocytes from major depression patients. International immunopharmacology. vol 4. issue 8. 2005-07-11. PMID:15270025. in lymphocytes from major depression patients, serotonin and 8-hydroxy-(dipropylamino)tetralin significantly increased camp levels, which was slightly reduced by way-100,135. 2005-07-11 2023-08-12 human
C Mizrahi, A Stojanovic, M Urbina, I Carreira, L Lim. Differential cAMP levels and serotonin effects in blood peripheral mononuclear cells and lymphocytes from major depression patients. International immunopharmacology. vol 4. issue 8. 2005-07-11. PMID:15270025. the present report indicates: (1) differential responses of immune cells from control individuals and depressed patients, with lower apparent adenylate cyclase activity in patient's cells; (2) variation in the population of cells, with responses to serotonergic agonists being lower in mononuclear cells and higher in lymphocytes from major depression patients; (3) increases of camp levels by serotonin and 5ht1a agonist in the patient's cells; and (4) evidence of impairment in serotonergic transduction systems in immune cells during depression. 2005-07-11 2023-08-12 human
Ph Quintin, P Thoma. [Efficacy of atypical antipsychotics in depressive syndromes]. L'Encephale. vol 30. issue 6. 2005-07-08. PMID:15738862. moreover, most of the atypical antipsychotics have a large action spectrum, beyond the only dopamine receptors: their effects on the serotonin receptors--particularly the 5-ht2a and 5-ht2c receptors--suggest that their association to ssri could be a promising treatment for depression. 2005-07-08 2023-08-12 Not clear
Philip J Cowen, Alan D Ogilvie, Joubert Gam. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Current medical research and opinion. vol 21. issue 3. 2005-07-05. PMID:15811202. recently, dualacting antidepressants, which block both serotonin (5-ht) and noradrenaline (na) reuptake, have been developed with the hope of improving depression treatment outcomes. 2005-07-05 2023-08-12 Not clear
Pavel Hamet, Johanne Trembla. Genetics and genomics of depression. Metabolism: clinical and experimental. vol 54. issue 5 Suppl 1. 2005-07-05. PMID:15877306. gene-environment interaction has been recognized for a long time in the pathophysiology of depression, and its best biological substratum at present is represented by the serotonin transporter (5-htt) gene, where several copies of its short allele culminate in depression and suicide in response to lifelong stress events. 2005-07-05 2023-08-12 mouse
Richard J Wurtma. Genes, stress, and depression. Metabolism: clinical and experimental. vol 54. issue 5 Suppl 1. 2005-07-05. PMID:15877307. the specific genetic locus causing serotonin uptake to be lower in some patients with major depression involves a polymorphic region (5-httlpr) in the promoter region of the gene for the uptake protein. 2005-07-05 2023-08-12 human